SageView Advisory Group
FLNA icon

SageView Advisory Group’s Filana Therapeutics FLNA Stock Holding History

SageView Advisory Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-110
Closed -$218 – 2074
2025
Q4 		$218 Buy
+110
New +$352 ﹤0.01% 2508

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GMT Capital
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

SageView Advisory Group's FLNA Position: Q1 2026 in Review

SageView Advisory Group sold out of Filana Therapeutics (FLNA) in Q1 2026, closing a stake of 110 shares — an estimated $218 sold.

SageView Advisory Group first reported a position in FLNA in Q4 2025 and held it in 1 quarter. The position peaked at $218 in Q4 2025. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • SageView Advisory Group reported no remaining Filana Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 110 Filana Therapeutics shares in Q1 2026, an estimated $218.
  • SageView Advisory Group first reported a position in Filana Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Filana Therapeutics position peaked at $218 in Q4 2025.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.